// App-Quantinova.ai

BSH2020‐OR‐039 : Updated results from the single‐arm, open‐label, long‐term efficacy and safety study of subcutaneous (SC) romiplostim in children with immune thrombocytopenia (ITP)

Researchers

Presenter

  • J. Grainger

Principal Investigators

  • J. Bussel

  • M. Tarantino

  • N. Cooper

  • D. Beam

  • J. Despotovic

  • A. Maschan

  • K. Wang

  • C. Bowers

  • M. Eisen

Medical Centers

  • Paediatric Haematology, Central Manchester Hospitals, Manchester, UK

  • Department of Pharmacology, Weill Cornell Medical College, New York, NY

  • The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine‐Peoria, Peoria, USA

  • Rheumatology Unit, Hammersmith Hospital, Imperial College London, London, United Kingdom

  • Cook Childrens Medical Center, Fort Worth, TX.

  • Texas Children's Hematology Center,Houston,United States

  • Dmitry Rogachev National Research Center for Pediatric Hematology, Moscow, Russian Federation

  • Biostats

  • Oncology Clinical Development, Amgen Inc., Thousand Oaks, CA

Locations

  • United Kingdom

  • United States

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • N/A

Drug/Treatment

  • Romiplostim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved